The week of April 20, 2026 finds the GLP-1 landscape fully in the oral-pill era, with Eli Lilly's Foundayo now in patients' hands and the FDA requiring additional long-term safety data. Meanwhile, a Stanford Medicine genetics study and a Johns Hopkins cardiovascular analysis added important real-world context for clinicians and patients.
FDA Action: Foundayo Approved, Post-Market Studies Required
The FDA reviewed the Foundayo application in just 50 days under its Commissioner's National Priority Voucher pilot program, making it the fastest approval of a new molecular entity since 2002. However, the approval came with strings attached. The FDA has told Eli Lilly to study possible heart, liver, and other risks tied to Foundayo, asking the company to study serious conditions such as heart attack, stroke, and drug-related liver injury, and also seeking more information on delayed stomach emptying; additionally, the FDA is requiring long-term research on a possible link to thyroid cancer. One physician noted that, as a newer non-peptide GLP-1, Foundayo does not yet have the same depth of safety data as the injectables, adding, "It doesn't mean a safety problem has been found" — the FDA also asked for a registry to track children with obesity who use weight loss drugs and another to monitor outcomes in pregnant patients.
Pricing and Access: Pills Starting at $149, Medicare Relief Coming in July
Eligible people with commercial insurance may pay as little as $25 per month with the Foundayo savings card, while individuals opting for self-pay can access Foundayo starting at $149 per month for the lowest dose; eligible Medicare Part D individuals may be able to get Foundayo for a reduced copay beginning July 1, 2026. Medicare enrollees in Part D or Medicare Advantage plans with drug coverage will see copays of around $50 a month for injectable Mounjaro, Ozempic, Wegovy, Zepbound, or the Wegovy pill after any deductibles, with the federal government paying $245 — a price that will also be available to state Medicaid programs. On the commercial insurance side, as of April 2026, approximately 50% of commercial insurance plans cover Zepbound for weight management, with plans that don't cover it usually citing its classification as a 'lifestyle' medication.
New Research: GLP-1 Resistance in 1 in 10 People; Benefits in Type 1 Diabetes
Stanford Medicine researchers discovered genetic variants in roughly 10% of people that reduce the effectiveness of GLP-1 diabetes drugs in regulating blood sugar; the decade-long international study analyzed clinical trials showing variant carriers achieved lower blood sugar control rates compared to non-carriers, and the findings could advance precision medicine by identifying patients unlikely to respond to GLP-1 drugs. Separately, a Johns Hopkins Bloomberg School of Public Health analysis of approximately 175,000 type 1 diabetes patients found encouraging outcomes: the five-year risk of major cardiovascular events such as heart attacks and the risk of end-stage kidney disease were reduced by 15% and 19%, respectively, for patients taking GLP-1 drugs such as semaglutide (Ozempic) and tirzepatide (Mounjaro). The study's authors cautioned that large clinical trials are ultimately needed to confirm these findings.
Manufacturer News: Novo Nordisk Partners with OpenAI; Wegovy HD Now Available
Novo Nordisk announced on April 14 a strategic partnership with OpenAI designed to deploy advanced AI across its entire business, from drug discovery to manufacturing, supply chain, and commercial operations; financial terms were not disclosed. The FDA had approved Wegovy HD, a higher-dose injectable version, on March 19 under a National Priority Voucher with a decision time of just 54 days, with clinical data showing average weight loss of 20.7% over 72 weeks; GoodRx announced on April 15 that Wegovy HD is now available at a self-pay price of $399 per month. On the pipeline front, Eli Lilly's retatrutide posted an impressive 28.7% mean weight loss at the highest dose in a 68-week Phase 3 study while also helping relieve knee pain in patients.
Market Context: Oral GLP-1 Competition Heats Up
The new Foundayo pill joins Novo Nordisk's oral Wegovy pill, which has spurred more than 600,000 prescriptions in the United States since it was approved in December 2025. Foundayo isn't as effective as Lilly's weekly shot Zepbound, but the once-daily pill could be attractive for people looking for convenience, and it can be scaled around the world. Both once-daily pills promise convenience, but orforglipron is a small-molecule GLP-1 drug that can be taken without food or water restrictions, while the Wegovy pill must be taken with a sip of water in the morning on an empty stomach, with a 30-minute wait before eating or drinking.